Stay updated with breaking news from John Rim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),
Samsung Biologics has entered into a strategic partnership with LegoChem Biosciences to advance ADC programmes aimed at treating solid tumours.
- Samsung Biologics to develop and manufacture antibody for ADC candidate - Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year INCHEON, South Korea, Feb. 7, 2024
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business...
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial...